ACT Biotech files SPA with FDA for telatinib mixture Phase 3 trial for tummy cancer ACT Biotech.

Related StoriesBrain wellness: how will you reduce cognitive decline? An interview with Heather Snyder, Ph.D. This content is normally republished with kind authorization from our close friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Policy Survey, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates. The Kaiser Daily Wellness Policy Report is published for, a free of charge service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Organization and Kaiser Family Basis.This pressure exists almost everywhere but is particularly intense in China. It is as a result no surprise that the most inventive ways to game the peer-review system to get manuscripts published attended from China. The firms mentioned above offering fake peer reviews all come from countries and China in Southeast Asia, and most of the authors involved with these cases come from the same areas. But it will be a mistake to check out this as a Chinese or Asian problem. The nagging problem may be the perverse incentive systems in scientific publishing. Provided that authors are rewarded for publishing many content articles and editors are rewarded for publishing them rapidly, new means of gaming the traditional publication versions will be invented quicker than new control procedures can be put in place.

A fresh age-related macular degeneration discovery Scientists have got won a major fight in the fight age-related macular degeneration, or AMD, a blinding eyesight disease that affects millions of people.